Pharmaceutical companies Moderna and Merck say a new melanoma vaccine tested in Pennsylvania is showing promising results. The vaccine uses messenger RNA technology and reportedly reduced the likelihood of recurrence by over 40 percent. Dr. Jason Luke at the University of Pittsburgh says the results are a potential watershed moment in cancer treatment therapy. Officials say nearly eight-thousand Americans die from skin cancer each year.